NWBO Research | Milton Maxwell

NWBO

Northwest Biotherapeutics, Inc.

0.2500

+0.0100+4.17%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

385.17M

P/E (TTM)

Basic EPS (TTM)

-0.06

Dividend Yield

Recent Filings

8-K

1/2/26Jan 2, 2026

8-K

Secures $5M convertible note

11/20/25Nov 20, 2025

Northwest Biotherapeutics secured a $5 million convertible promissory note from Yorkville on November 14, 2025, funding Sawston, UK facility construction and operations. The 12-month note carries 5% OID, no interest, and converts at a discount to market price, capped at 1/5 monthly unless above $0.29. Funds target first Grade C manufacturing suite. No payments due until maturity.

10-Q

Q3 FY2025 results

11/14/25Nov 14, 2025

Northwest Biotherapeutics narrowed its Q3 operating loss to $14.3M from $14.8M y/y, while nine-month operating loss eased to $46.4M from $48.0M y/y (derived), as R&D expenses dipped to $7.5M from $8.1M on lower manufacturing costs and stock comp. Revenues ticked up slightly to $200K from $357K y/y. Cash climbed to $4.6M from $2.2M year-end, fueled by $17.3M in equity raises and $12.7M new convertible notes, yet ops burned $30M y/y. Closed Advent BioServices acquisition Oct 24, 2025 for £1.4M cash plus net payables, gaining cryostorage assets with 19M company securities reverting—no goodwill noted. Debt stack hit $72.2M carrying value. Diluted EPS held at $(0.02), anti-dilutive. Cash burn persists.

8-K

Secures $5.5M loan

10/31/25Oct 31, 2025

Northwest Biotherapeutics secured a $5,505,000 commercial loan from Streeterville Capital on October 27, 2025, maturing in 22 months with no repayments for the first 8 months and 14 amortized installments thereafter at 110% of principal plus 8% interest. It carries a 10% original issue discount and prepayment option with a 10% charge. Funds fuel ongoing operations. Default risks acceleration.

8-K

10/30/25Oct 30, 2025

About

Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

CEO

Ms. Linda F. Powers J.D.

IPO

12/14/2001

Website

https://www.nwbio.com

Employees

Sector

Healthcare

Industry

Biotechnology